Clinical Trial: A Multicenter, Randomized, Double-blind, Parallel, Positive-controlled Phase III Clinical Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection (DUPIXENT®) in Participants with Moderate to Severe Atopic Dermatitis (China)

China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Randomized, Double-blind, Parallel, Positive-controlled Phase III Clinical Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection (DUPIXENT®) in Participants with Moderate to Severe Atopic Dermatitis'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132741

Registration Time: 2026/09/17

Type: Interventional study

Primary Sponsor: Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340316

Published by HT Digital Content Services with p...